KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Aurinia Pharmaceuticals (AUPH) Return on Sales: 2019-2025

Historic Return on Sales for Aurinia Pharmaceuticals (AUPH) over the last 5 years, with Sep 2025 value amounting to 0.29%.

  • Aurinia Pharmaceuticals' Return on Sales rose 40.00% to 0.29% in Q3 2025 from the same period last year, while for Sep 2025 it was 0.29%, marking a year-over-year increase of 40.00%. This contributed to the annual value of 0.02% for FY2024, which is 47.00% up from last year.
  • As of Q3 2025, Aurinia Pharmaceuticals' Return on Sales stood at 0.29%, which was up 25.69% from 0.23% recorded in Q2 2025.
  • In the past 5 years, Aurinia Pharmaceuticals' Return on Sales ranged from a high of 0.29% in Q3 2025 and a low of -3.97% during Q4 2021.
  • Over the past 3 years, Aurinia Pharmaceuticals' median Return on Sales value was -0.24% (recorded in 2024), while the average stood at -0.18%.
  • Within the past 5 years, the most significant YoY rise in Aurinia Pharmaceuticals' Return on Sales was 55,328bps (2021), while the steepest drop was 193bps (2021).
  • Over the past 5 years, Aurinia Pharmaceuticals' Return on Sales (Quarterly) stood at -3.97% in 2021, then surged by 316bps to -0.81% in 2022, then spiked by 36bps to -0.44% in 2023, then spiked by 47bps to 0.02% in 2024, then spiked by 40bps to 0.29% in 2025.
  • Its Return on Sales was 0.29% in Q3 2025, compared to 0.23% in Q2 2025 and 0.16% in Q1 2025.